-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

Benzinga·09/14/2026 17:47:17
Listen to the news
B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $123 to $144.